Antibodies for use in agrin-deficient disorders

An anti-MuSK antibody targeting the MuSK Frizzled-like domain addresses the inadequacies of current agrin deficiency treatments by enhancing MuSK phosphorylation, improving neuromuscular transmission and muscle strength, providing a promising therapeutic approach for agrin deficiency-related disorders.

WO2024235870A1PCT designated stage expired Publication Date: 2024-11-21ARGENX BVBA(BE)
View PDF 10 Cites 0 Cited by

Patent Information

Application Number
PCT/EP2024/062981
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-07-28
Filing Date
2024-05-10
Publication Date
2024-11-21

AI Technical Summary

Technical Problem

Current treatments for agrin deficiency-related disorders, such as congenital myasthenic syndromes, are inadequate, with existing medications like acetylcholinesterase inhibitors and 3,4-diaminopyridine being ineffective for specific subtypes and lacking standardized guidelines, leading to unsatisfactory symptom management and limited therapeutic options.

Method used

Development of an anti-MuSK antibody-based molecule that binds to the MuSK Frizzled-like domain, capable of activating MuSK phosphorylation, which is essential for neuromuscular junction development and maintenance, to treat agrin deficiency-related disorders by mimicking or enhancing the natural agrin-LRP4 interaction.

Benefits of technology

The anti-MuSK antibody improves neuromuscular transmission, increases muscle strength, and stabilizes neuromuscular junctions, offering a potential therapeutic solution for agrin deficiency-related disorders by enhancing MuSK signaling and phosphorylation, thereby addressing the limitations of existing treatments.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 000156
    Figure 000156
  • Figure 000157
    Figure 000157
  • Figure 000158
    Figure 000158
Patent Text Reader

Abstract

The present invention relates to a MuSK antibody-based molecule for use in the prevention or treatment of a disease or condition resulting from Agrin deficiency in a human subject.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Recombinant altered antibodies and methods of making altered antibodies

    US5225539A

  • Humanized immunoglobulins

    US5530101A

  • Humanized immunoglobulins

    US5585089A

  • Antibodies with altered effector functions

    US5624821A

  • DNA encoding antibodies with altered effector functions

    US5648260A